The Endometrial Cancer market is projected to witness substantial expansion over the forecast period, primarily driven by rising disease prevalence, increasing awareness, and the anticipated launch of multiple late-stage pipeline therapies. The introduction of innovative treatment options is expected to significantly reshape market dynamics and therapeutic approaches.
DelveInsight’s report, “Endometrial Cancer Market Insights, Epidemiology, and Market Forecast–2034,” provides a comprehensive evaluation of disease epidemiology, treatment paradigms, emerging therapies, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan (7MM).
Get a Free sample for the Endometrial Cancer Market Report:
https://www.delveinsight.com/report-store/endometrial-cancer-market
The report offers detailed coverage of approved and pipeline drugs, current treatment algorithms, individual therapy market shares, and projected market size from 2020 to 2034. It further assesses key market drivers, barriers, and unmet medical needs to identify future growth opportunities.
Endometrial Cancer Overview
Endometrial cancer originates in the inner lining of the uterus (endometrium). This lining undergoes cyclical changes during menstruation. Malignant transformation of endometrial cells leads to tumor development, most commonly affecting postmenopausal women.
Key Endometrial Cancer Market Insights
- The Endometrial Cancer market is expected to grow at a notable CAGR during 2020–2034.
- In June 2025, Daiichi Sankyo initiated dosing of the first patient in the DESTINY-Endometrial01 trial evaluating Enhertu (trastuzumab deruxtecan) combined with rilvegostomig or Merck’s Keytruda (pembrolizumab) as first-line therapy for HER2-expressing, mismatch repair proficient (pMMR) advanced or recurrent disease.
- In May 2025, Kaida BioPharma entered a manufacturing partnership with Northway Biotech to produce KAD101, a prolactin receptor antagonist being developed for platinum-resistant ovarian cancer, with expansion potential into endometrial cancer treatment.
- PRISM BioLab and Eisai announced updated findings from a Phase Ib study evaluating E7386 combined with Lenvatinib, including an expansion cohort of advanced endometrial cancer patients who progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy.
- Combination strategies targeting the PI3K/AKT/mTOR and MAPK/ERK pathways continue to be explored. While mTOR inhibitors such as everolimus (Afinitor) and temsirolimus (Torisel) have been evaluated in multiple regimens, clinical benefits have demonstrated modest outcomes.
- Key Companies: AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, ARIAD Pharmaceuticals, and Others
- Faeth Therapeutics and The GOG Foundation initiated a Phase II trial investigating PIKTOR (serabelisib + sapanisertib) combined with paclitaxel, targeting cancer metabolism through dual PI3Kα-mTORC1/2 inhibition.
- Phase III RUBY trial results for patients with advanced dMMR/MSI-H endometrial cancer were presented at the 2024 ASCO Annual Meeting.
Endometrial Cancer Epidemiology Highlights
- Approximately 3 in 100 women are expected to develop uterine cancer during their lifetime (National Cancer Institute).
- Around 80% of patients survive five years or longer after diagnosis.
- Endometrial cancer accounts for roughly 4% of cancers in women worldwide.
- In the United States, it is the most common cancer of the female reproductive system.
- The UK reports nearly 9,700 new uterine cancer cases annually.
- Globally, approximately 380,000 new cases and 89,000 deaths occur each year.
- In Japan, more than 14,900 new cases are diagnosed annually, ranking it among the top 10 most common cancers in women.
To Know in detail about the Endometrial Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometrial Cancer Market Forecast
Endometrial Cancer Market Dynamics
The Endometrial Cancer market landscape is expected to evolve considerably due to:
- Launch of innovative targeted therapies
- Increasing adoption of immunotherapy combinations
- Molecular profiling integration into routine clinical practice
- Advances in biomarker-driven treatment selection
Endometrial Cancer Epidemiology Segmentation (2020–2034, 7MM)
- Total incident cases
- Stage-specific distribution
- Age-specific incidence
- Drug-treated patient population by therapy line
The epidemiology analysis provides insights into historical patterns, current burden, and forecasted patient pools using clinical research data and expert perspectives.
Endometrial Cancer Drug Uptake and Pipeline Analysis
The report evaluates:
- Adoption trends of newly approved and upcoming therapies
- Drug-wise market share projections
- Patient uptake rates by treatment line
- Sales performance forecasting
It also reviews pipeline development activities, including clinical trial progress, licensing agreements, collaborations, mergers & acquisitions, and patent intelligence shaping the future competitive landscape.
Key Companies in the Endometrial Cancer Market
- Eli Lilly
- AstraZeneca
- Karyopharm Therapeutics
- Evergreen Therapeutics
- Abbott Laboratories
- ARIAD Pharmaceuticals
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Siemens Healthineers, and others
Key Endometrial Cancer Therapies
- Imlunestrant – Eli Lilly
- Lynparza (Olaparib) + Imfinzi – AstraZeneca
- Selinexor – Karyopharm Therapeutics
- EG-007 – Evergreen Therapeutics
Endometrial Cancer Market Strengths
- Transformative clinical advancements over the past decade
- Improved pathological classification and molecular stratification
- Standardized reporting and diagnostic accuracy
- Integration of ancillary molecular testing in treatment decision-making
Endometrial Cancer Market Opportunities
- Expansion of immunotherapy-based combinations
- Growth in DNA repair-targeted therapies
- Molecular subgroup-driven personalized treatment approaches
- Rapid evolution of genomic profiling and precision oncology strategies
Scope of the Endometrial Cancer Market Report
- Study Period: 2020–2034
- Geographic Coverage: United States, EU5, Japan
- Therapeutic Assessment: Marketed and emerging therapies
- Market Dynamics: Drivers, barriers, and competitive landscape
- Analytical Frameworks: SWOT, PESTLE, Porter’s Five Forces, BCG Matrix
- Additional Insights: Unmet needs, reimbursement trends, KOL and analyst perspectives
Discover more about therapies set to grab major Endometrial Cancer market share @ Endometrial Cancer Treatment Landscape
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
